Skip to main content
Triangle logo TriangleGet started

Melphalan/HDS Followed by… (NCT06607458)

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease: a one-minute explainerNCT066074581 min

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab trial for Refractory Metastatic Colorectal Cancer (NCT06607458). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with treatment-resistant metastatic colorectal cancer concentrated in the liver. Liver tumors must occupy no more than half the liver; only limited disease elsewhere is allowed.

The idea: test two liver-artery infusions of melphalan, a DNA-damaging chemotherapy, under general anesthesia, followed by trifluridine-tipiracil plus bevacizumab. The comparison group receives trifluridine-tipiracil plus bevacizumab alone. Researchers measure time before liver disease progresses.

This phase 2 study plans 90 patients. Marwan Fakih leads at City of Hope in Duarte, with nine recruiting US sites. Delcath sponsors it. Previous trifluridine-tipiracil is excluded.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.